Revvity Inc.

RVTY Healthcare Diagnostics & Research

Revvity Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 3.67% from fiscal 2024. In the quarter to June 2026, revenue grew 1.31%, EPS grew 2.17%, free cash flow grew 59.3% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.

152.64 2.07 −1.34%
Market cap
$17.3B
P/E
72.7×
Fwd P/E
37.5×
Dividend yield
0.23%
F-score
6/9
Altman Z
2.49
Beneish M
−2.45
Dividend safety
80/100

Revvity Inc. (RVTY) Revenue growth

Alert me on Revenue growth

Revvity Inc.'s revenue growth over the twelve months to 30 June 2026 was 4.05%, up 0.4 percentage points from fiscal 2025 (3.67%). Over the past ten years it has ranged from −17.0% (fiscal 2023) to 43.7% (fiscal 2021); the current reading is higher than 64% of that period. That is below the Diagnostics & Research industry median of 7.69% and below the Healthcare sector median of 8.27%.

Revenue growth, annual

Embed this chart

Annual newest first

Period Revenue growth Change (points)
FY2025 3.67% 3.51
FY2024 0.16% 17.11
FY2023 −17.0% (3.47)
FY2022 −13.5% (57.21)
FY2021 43.7% 51.37
FY2020 −7.64% (11.44)
FY2019 3.80% (19.28)
FY2018 23.1% 16.39
FY2017 6.69% 6.18
FY2016 0.51% (1.18)

Quarterly newest first

Period Revenue growth Change (points)
Jun 2026 1.31% (5.66)
Mar 2026 6.97% 1.12
Dec 2025 5.85% 3.67
Sep 2025 2.18% (1.95)
42 more quarters

Against its own ten years

Low −17.0% High 43.7%
Ten-year median 1.69%
Current reading's percentile 64

Revenue growth against peers

What Revenue growth is

Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.

(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|

The full definition of Revenue growth →

More on RVTY